216 related articles for article (PubMed ID: 11106549)
1. Matrix metalloproteinase 9 promoter activity is induced coincident with invasion during tumor progression.
Kupferman ME; Fini ME; Muller WJ; Weber R; Cheng Y; Muschel RJ
Am J Pathol; 2000 Dec; 157(6):1777-83. PubMed ID: 11106549
[TBL] [Abstract][Full Text] [Related]
2. Matrix metalloproteinases play an active role in Wnt1-induced mammary tumorigenesis.
Blavier L; Lazaryev A; Dorey F; Shackleford GM; DeClerck YA
Cancer Res; 2006 Mar; 66(5):2691-9. PubMed ID: 16510589
[TBL] [Abstract][Full Text] [Related]
3. Long-term exposure to elevated levels of circulating TIMP-1 but not mammary TIMP-1 suppresses growth of mammary carcinomas in transgenic mice.
Yamazaki M; Akahane T; Buck T; Yoshiji H; Gomez DE; Schoeffner DJ; Okajima E; Harris SR; Bunce OR; Thorgeirsson SS; Thorgeirsson UP
Carcinogenesis; 2004 Sep; 25(9):1735-46. PubMed ID: 15166086
[TBL] [Abstract][Full Text] [Related]
4. Mena deficiency delays tumor progression and decreases metastasis in polyoma middle-T transgenic mouse mammary tumors.
Roussos ET; Wang Y; Wyckoff JB; Sellers RS; Wang W; Li J; Pollard JW; Gertler FB; Condeelis JS
Breast Cancer Res; 2010; 12(6):R101. PubMed ID: 21108830
[TBL] [Abstract][Full Text] [Related]
5. Overexpression of membrane-type matrix metalloproteinase-1 gene induces mammary gland abnormalities and adenocarcinoma in transgenic mice.
Ha HY; Moon HB; Nam MS; Lee JW; Ryoo ZY; Lee TH; Lee KK; So BJ; Sato H; Seiki M; Yu DY
Cancer Res; 2001 Feb; 61(3):984-90. PubMed ID: 11221894
[TBL] [Abstract][Full Text] [Related]
6. Overexpression of TIMP-1 under the MMP-9 promoter interferes with wound healing in transgenic mice.
Salonurmi T; Parikka M; Kontusaari S; Pirilä E; Munaut C; Salo T; Tryggvason K
Cell Tissue Res; 2004 Jan; 315(1):27-37. PubMed ID: 14569458
[TBL] [Abstract][Full Text] [Related]
7. Synergistic interaction of transforming growth factor alpha and c-myc in mouse mammary and salivary gland tumorigenesis.
Amundadottir LT; Johnson MD; Merlino G; Smith GH; Dickson RB
Cell Growth Differ; 1995 Jun; 6(6):737-48. PubMed ID: 7669729
[TBL] [Abstract][Full Text] [Related]
8. Inducible and coupled expression of the polyomavirus middle T antigen and Cre recombinase in transgenic mice: an in vivo model for synthetic viability in mammary tumour progression.
Rao T; Ranger JJ; Smith HW; Lam SH; Chodosh L; Muller WJ
Breast Cancer Res; 2014 Jan; 16(1):R11. PubMed ID: 24457046
[TBL] [Abstract][Full Text] [Related]
9. Decreased tumor formation in 7,12-dimethylbenzanthracene-treated stromelysin-1 transgenic mice is associated with alterations in mammary epithelial cell apoptosis.
Witty JP; Lempka T; Coffey RJ; Matrisian LM
Cancer Res; 1995 Apr; 55(7):1401-6. PubMed ID: 7882342
[TBL] [Abstract][Full Text] [Related]
10. The matrix metalloproteinase matrilysin influences early-stage mammary tumorigenesis.
Rudolph-Owen LA; Chan R; Muller WJ; Matrisian LM
Cancer Res; 1998 Dec; 58(23):5500-6. PubMed ID: 9850086
[TBL] [Abstract][Full Text] [Related]
11. Maspin expression inversely correlates with breast tumor progression in MMTV/TGF-alpha transgenic mouse model.
Reddy KB; McGowen R; Schuger L; Visscher D; Sheng S
Oncogene; 2001 Oct; 20(45):6538-43. PubMed ID: 11641778
[TBL] [Abstract][Full Text] [Related]
12. SV40 T/t-antigen induces premature mammary gland involution by apoptosis and selects for p53 missense mutation in mammary tumors.
Tzeng YJ; Zimmermann C; Guhl E; Berg B; Avantaggiati ML; Graessmann A
Oncogene; 1998 Apr; 16(16):2103-14. PubMed ID: 9572491
[TBL] [Abstract][Full Text] [Related]
13. Expression of matrix metalloproteinase (MMP)-2, MMP-9, MMP-13, and MT1-MMP in skin tumors of human papillomavirus type 8 transgenic mice.
Akgül B; Pfefferle R; Marcuzzi GP; Zigrino P; Krieg T; Pfister H; Mauch C
Exp Dermatol; 2006 Jan; 15(1):35-42. PubMed ID: 16364029
[TBL] [Abstract][Full Text] [Related]
14. Tumor endothelium-specific transgene expression directed by vascular endothelial growth factor receptor-2 (Flk-1) promoter/enhancer sequences.
Heidenreich R; Kappel A; Breier G
Cancer Res; 2000 Nov; 60(21):6142-7. PubMed ID: 11085538
[TBL] [Abstract][Full Text] [Related]
15. The C3(1)/SV40 T-antigen transgenic mouse model of mammary cancer: ductal epithelial cell targeting with multistage progression to carcinoma.
Green JE; Shibata MA; Yoshidome K; Liu ML; Jorcyk C; Anver MR; Wigginton J; Wiltrout R; Shibata E; Kaczmarczyk S; Wang W; Liu ZY; Calvo A; Couldrey C
Oncogene; 2000 Feb; 19(8):1020-7. PubMed ID: 10713685
[TBL] [Abstract][Full Text] [Related]
16. Mouse mammary tumor virus p75 and p110 CUX1 transgenic mice develop mammary tumors of various histologic types.
Cadieux C; Kedinger V; Yao L; Vadnais C; Drossos M; Paquet M; Nepveu A
Cancer Res; 2009 Sep; 69(18):7188-97. PubMed ID: 19738070
[TBL] [Abstract][Full Text] [Related]
17. Metastasis tumor antigen family proteins during breast cancer progression and metastasis in a reliable mouse model for human breast cancer.
Zhang H; Stephens LC; Kumar R
Clin Cancer Res; 2006 Mar; 12(5):1479-86. PubMed ID: 16533771
[TBL] [Abstract][Full Text] [Related]
18. MMTV promoter hypomethylation is linked to spontaneous and MNU associated c-neu expression and mammary carcinogenesis in MMTV c-neu transgenic mice.
Zhou H; Chen WD; Qin X; Lee K; Liu L; Markowitz SD; Gerson SL
Oncogene; 2001 Sep; 20(42):6009-17. PubMed ID: 11593408
[TBL] [Abstract][Full Text] [Related]
19. MT1-MMP is required for efficient tumor dissemination in experimental metastatic disease.
Szabova L; Chrysovergis K; Yamada SS; Holmbeck K
Oncogene; 2008 May; 27(23):3274-81. PubMed ID: 18071307
[TBL] [Abstract][Full Text] [Related]
20. 2-difluoromethylornithine and dehydroepiandrosterone inhibit mammary tumor progression but not mammary or prostate tumor initiation in C3(1)/SV40 T/t-antigen transgenic mice.
Green JE; Shibata MA; Shibata E; Moon RC; Anver MR; Kelloff G; Lubet R
Cancer Res; 2001 Oct; 61(20):7449-55. PubMed ID: 11606379
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
